Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Obseva Sa (OBSV)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 593,475
  • Shares Outstanding, K 45,477
  • Annual Sales, $ 0 K
  • Annual Income, $ -76,720 K
  • 60-Month Beta 1.16
  • Price/Sales 59,347.50
  • Price/Cash Flow N/A
  • Price/Book 4.77

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.57
  • Number of Estimates 5
  • High Estimate -0.54
  • Low Estimate -0.60
  • Prior Year -0.49
  • Growth Rate Est. (year over year) -16.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.82 +10.41%
on 05/13/19
14.35 -9.08%
on 04/24/19
+0.18 (+1.40%)
since 04/17/19
3-Month
11.76 +10.97%
on 02/19/19
14.50 -10.00%
on 04/15/19
+0.67 (+5.41%)
since 02/15/19
52-Week
10.23 +27.57%
on 12/26/18
20.35 -35.87%
on 06/18/18
-0.35 (-2.61%)
since 05/17/18

Most Recent Stories

More News
ObsEva SA to Participate in Upcoming Investor Conferences

Geneva, Switzerland and Boston, MA - May 16, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics...

OBSV : 13.05 (-0.15%)
ObsEva SA (OBSV) Reports Q1 Loss, Lags Revenue Estimates

ObsEva SA (OBSV) delivered earnings and revenue surprises of -18.00% and -50.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

OBSV : 13.05 (-0.15%)
ObsEva Reports First Quarter 2019 Financial Results

OBSV : 13.05 (-0.15%)
ObsEva SA Announces Initiation of Phase 3 EDELWEISS 2 and 3 Trials of Linzagolix for Endometriosis Associated Pain in U.S., Canada and Europe

Geneva, Switzerland and Boston, MA - May 9, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics...

OBSV : 13.05 (-0.15%)
ObsEva SA Announces that ObsEva's Shareholders Approved all Board Proposals at its 2019 Annual General Meeting held on May 8, 2019

Geneva, Switzerland and Boston, MA - May 8, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics...

OBSV : 13.05 (-0.15%)
Consolidated Research: 2019 Summary Expectations for Corporacion America Airports S.A., Nasdaq, Constellation Brands, and ObsEva SA -- Fundamental Analysis, Key Performance Indications

In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Corporacion America Airports S.A....

CAAP : 7.85 (-1.01%)
NDAQ : 90.30 (-0.69%)
OBSV : 13.05 (-0.15%)
STZ : 204.79 (-0.97%)
ObsEva SA Reports Consistent Long-Term Findings from Phase 2b EDELWEISS trial of Linzagolix for Endometriosis-Associated Pain

OBSV : 13.05 (-0.15%)
ObsEva SA to Hold First Quarter 2019 Financial Results and Business Update Call on May 9, 2019

Geneva, Switzerland and Boston, MA -May 1, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics...

OBSV : 13.05 (-0.15%)
ObsEva SA Reports Further Infant Follow-up Data from IMPLANT2 Trial Echoing Favorable Safety Profile of Nolasiban in IVF

Geneva, Switzerland and Boston, MA - April 29 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics...

OBSV : 13.05 (-0.15%)
Publication of ObsEva SA Invitation to 2019 Annual General Meeting of Shareholders

Geneva, Switzerland and Boston, MA - March 29, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics...

OBSV : 13.05 (-0.15%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators are in flux.

See More Share

Trade OBSV with:

Business Summary

ObsEva SA is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics for woman's reproductive health and pregnancy. ObsEva SA is headquartered in Geneva, Switzerland.

See More

Key Turning Points

2nd Resistance Point 13.40
1st Resistance Point 13.23
Last Price 13.05
1st Support Level 12.70
2nd Support Level 12.34

See More

52-Week High 20.35
Fibonacci 61.8% 16.48
Fibonacci 50% 15.29
Fibonacci 38.2% 14.10
Last Price 13.05
52-Week Low 10.23

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar